Overview: HTLV I II Antibody Confirmatory TestIntroduction: The HTLV I II Antibody Confirmatory Test confirms HTLV-I/II antibodies to diagnose infection, causing neurological issues or leukemia. Aligned with 2023 WHO guidelines, it uses immunoassays for high specificity, supporting infectious disease screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected HTLV infection.
Other Names: HTLV I/II Antibody Assay, HTLV Confirmatory Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: HTLV testing began in the 1980s with the discovery of HTLV-I. Immunoassay-based confirmatory tests improved in the 2000s, enhancing diagnostic precision.
Purpose: Confirms HTLV-I/II antibodies to diagnose infection, guides treatment, and evaluates patients with neurological issues or leukemia.
Test Parameters: 1. HTLV I/II Antibodies
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like neurological issues, leukemia, or history of high-risk exposures.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Transport in a biohazard bag.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neurological symptoms, leukemia, or high-risk exposures (e.g., blood transfusions, IV drug use). Include current medications and recent symptoms.
Consent: Written consent required, detailing the tests purpose, infection implications, and potential need for antiviral or oncology treatment.
Procedural Considerations: Uses immunoassays to confirm HTLV-I/II antibodies. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for infectious disease confirmation.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Cross-reactivity with other retroviruses may cause false positives.
Clinical Significance: Positive HTLV-I/II antibodies confirm infection, guiding antiviral therapy or leukemia management. Negative results may require molecular testing.
Specialist Consultation: Consult an infectious disease specialist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: HTLV PCR, Western blot, or imaging to confirm HTLV infection or leukemia.
Test Limitations: False positives may occur due to cross-reactivity. Clinical correlation and confirmatory testing are needed.
References: WHO HTLV Guidelines, 2023; Journal of Infectious Diseases, Gessain A, 2022.
